煙臺東(dong)誠藥(yao)業集(ji)團(tuan)股(gu)份有(you)限(xian)公司(si)(前(qian)身為煙臺東(dong)誠生化(hua)股(gu)份有(you)限(xian)公司(si))成(cheng)立于1998年(nian),2012年(nian)5月(yue)在深交所上市(股(gu)票(piao)代碼(ma)002675)。歷(li)經20余年(nian)的發展,東(dong)誠藥(yao)業現(xian)已成(cheng)為一(yi)家覆(fu)蓋(gai)生化(hua)原料(liao)藥(yao)、化(hua)藥(yao)、中成(cheng)藥(yao)、核藥(yao)四大領域,融藥(yao)品研發、生產(chan)、銷售于一(yi)體的大型制(zhi)藥(yao)企業集(ji)團(tuan)。
集(ji)團控股煙臺(tai)(tai)東誠(cheng)(cheng)北(bei)方制藥(yao)(yao)(yao)有(you)限(xian)(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)、煙臺(tai)(tai)東誠(cheng)(cheng)大(da)洋(yang)制藥(yao)(yao)(yao)有(you)限(xian)(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)、臨沂東誠(cheng)(cheng)東源(yuan)生(sheng)物(wu)工(gong)程(cheng)有(you)限(xian)(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)、中泰(tai)生(sheng)物(wu)制品(pin)有(you)限(xian)(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)、東誠(cheng)(cheng)國際(ji)(香港)有(you)限(xian)(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)、成都云(yun)克藥(yao)(yao)(yao)業有(you)限(xian)(xian)責任公(gong)(gong)(gong)司(si)(si)(si)(si)、上(shang)海(hai)欣科(ke)醫藥(yao)(yao)(yao)有(you)限(xian)(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)、上(shang)海(hai)益泰(tai)醫藥(yao)(yao)(yao)科(ke)技有(you)限(xian)(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)、南京(jing)江(jiang)原安迪(di)科(ke)正(zheng)電(dian)子研究發展有(you)限(xian)(xian)公(gong)(gong)(gong)司(si)(si)(si)(si)等(deng)40多家分子公(gong)(gong)(gong)司(si)(si)(si)(si),集(ji)團在北(bei)京(jing)、上(shang)海(hai)、南京(jing)設(she)立(li)研發分支(zhi)機(ji)構和辦事處,擁(yong)有(you)員(yuan)工(gong)近兩千人。
東誠(cheng)藥業作為國內前(qian)沿(yan)的生(sheng)化原料藥生(sheng)產(chan)企業,核心產(chan)品(pin)肝素鈉(na)及硫(liu)酸(suan)軟(ruan)骨素憑借優質質量,贏得了眾多(duo)的國際機構認證,產(chan)品(pin)90%以上銷往歐洲、美洲、亞(ya)太等(deng)全球(qiu)40多(duo)個國家和地區,與眾多(duo)國際知(zhi)名藥企建立了穩(wen)定(ding)的合(he)作關系。
東誠藥(yao)業(ye)不斷(duan)強化制劑(ji)業(ye)務,制劑(ji)產品覆(fu)蓋心(xin)血管(guan)、抗(kang)腫瘤、泌尿、骨科等治療(liao)領域(yu)。近年來,公(gong)(gong)司高起點進入高技術壁壘和高成長性的核醫(yi)(yi)藥(yao)行業(ye),相(xiang)繼并購國(guo)內多(duo)家核藥(yao)企業(ye),完成從診斷(duan)用(yong)核藥(yao)到治療(liao)用(yong)核藥(yao)的全產業(ye)鏈(lian)布局,奠定了(le)公(gong)(gong)司在中(zhong)國(guo)核醫(yi)(yi)藥(yao)領域(yu)的前沿地(di)位。
東誠藥業不斷(duan)加(jia)大科研投入(ru),致力自主創新(xin)(xin),引進(jin)泰山學者、973科學家等高素質人才。通過(guo)建立廣泛(fan)的(de)產學研合作(zuo)網絡(luo),實現新(xin)(xin)技術(shu)的(de)引進(jin)轉化,通過(guo)創新(xin)(xin)驅動帶領企業發(fa)展。
在“立足東(dong)(dong)方,誠諾健康”企(qi)(qi)業(ye)(ye)使命指引下,東(dong)(dong)誠藥(yao)(yao)業(ye)(ye)將深(shen)化資源(yuan)整合、優化產業(ye)(ye)結構、不斷提(ti)升企(qi)(qi)業(ye)(ye)創(chuang)新能力與核心競爭力,以“全球肝素專家,中(zhong)國核藥(yao)(yao)領(ling)軍企(qi)(qi)業(ye)(ye)”為(wei)目標,向著(zhu)成長(chang)為(wei)專業(ye)(ye)領(ling)域(yu)前沿的、持續創(chuang)造優異價值的制藥(yao)(yao)企(qi)(qi)業(ye)(ye)不斷邁進。